Artificial intelligence is no longer an abstract, futuristic concept in arbitration proceedings. It's here and is not leaving anytime soon. So how do we make sure it behaves?

Databricks' KARL agent uses reinforcement learning to generalize across six enterprise search behaviors — the problem that breaks most RAG pipelines.

The US government's release of millions of pages related to convicted sex offender Jeffrey Epstein has ignited a torrent of misinformation online, including posts claiming one redacted picture from ...

Abstract: Medical images are usually collected from multiple clinical centers with various types of scanners. When confronted with such significant cross-domain distribution discrepancy, a deep ...

The company behind Claude says it would rather lose defence work than weaken its ban on autonomous weapons and domestic surveillance.

Transform your everyday photos into cinematic Holi celebration images using Google Gemini Nano Banana Pro with detailed ...

Sign up for the Slatest to get the most insightful analysis, criticism, and advice out there, delivered to your inbox daily. After months of watching federal agents ...

The developers of the Z-Image-Turbo model stated that the model's languages are Chinese and English. However, its test encoder Qwen 3 knows Russian perfectly well! As a result, the Z-Image-Turbo model ...

Airplane flight path banner Abstract polygonal image of flying airplane Digital 3d airplane flying over clouds. Abstract vector wireframe of airliner in the sky. Travel, tourism, business, ...

Artificial intelligence (AI) tools, including large language models (LLMs), are rapidly finding their way into everyday medicine. Nowadays, it is not uncommon for physicians to be questioned by ...

Chethan is a reporter at Android Police, focusing on the weekend news coverage for the site. He has covered tech for over a decade with multiple publications, including the likes of Times Internet, ...

In the CheckMate 238 trial, patients with resected stage IIIB–C or stage IV melanoma who were treated with nivolumab had longer recurrence-free survival than those who received ipilimumab. Data were ...